Dialyzability of gadodiamide in hemodialysis patients.
Dialyzability of gadodiamide in hemodialysis patients.
复制标题
DOI：
10.1007/s11604-006-0055-9
复制
发表时间：
2006-07-01
影响因子：
--
通讯作者：
Nagura, Yuji
中科院分区：
文献类型：
--
作者：
Saitoh, Tomoya;Hayasaka, Kazumasa;Nagura, Yuji
目的：本研究的目的是评估加多二胺在血液透析患者中的造影剂增强、药代动力学、透析性和安全性。材料与方法：对13例伴有腹部疾病的血液透析患者静脉注射加多二胺（0.1 mmol/kg体重）后进行磁共振成像（MRI）检查，分别于第1、3、5、8天透析。在第一次血液透析之前、期间和结束时，以及在接下来的三次血液透析之前和结束时，采集血液样本。测定全血细胞计数、血液生化、β -微球蛋白、钆含量。在第一次血液透析期间评估尿素、肌酐和钆的透析。两名放射科医生回顾了对比前和对比后的MRI和gd增强MR血管造影（MRA）图像并进行了视觉评估；他们的评价是基于共识的。结果：加多双胺未引起肾功能改变。在第一次、第二次和第三次血液透析结束时，平均分别有73.8%、92.4%和98.9%的加多二胺剂量被消除。gadodiamide的平均半衰期为1.93 h （SD 0.55）。血液透析期间加多二胺的平均清除率为63.5 ml/min （SD 21.9）。注射加多二胺无副作用。在所有病例中，血液透析患者注射加多二胺后获得可诊断的MRI和MRA图像。结论：在血液透析患者中，加多二胺达到了可诊断的图像。它是可透析的，可以安全使用，无需采取措施增加排泄。
PURPOSE: The aim of this study was to evaluate the contrast enhancement, pharmacokinetics, dialyzability, and safety of gadodiamide in patients on hemodialysis.MATERIALS AND METHODS: Thirteen hemodialysis patients with abdominal disease were examined after receiving intravenous gadodiamide (0.1 mmol/kg body weight) by magnetic resonance imaging (MRI) and were dialyzed at l, 3, 5, and 8 days. Blood samples were obtained immediately before, during, and at the end of the first hemodialysis session and immediately before and at the end of the next three sessions. The complete blood count, blood biochemistry, beta2-microglobulin, and gadolinium were measured. Dialysis of urea, creatinine, and gadolinium during the first hemodialysis session was assessed. Precontrast and postcontrast MRI and Gd-enhanced MR angiography (MRA) images were reviewed and visually evaluated by two radiologists; their evaluation was based on consensus.RESULTS: Gadodiamide did not cause any changes in renal function. An average of 73.8%, 92.4%, and 98.9% of the gadodiamide dose was eliminated by the end of the first, second, and third hemodialysis sessions, respectively. The average half-time of gadodiamide was 1.93 h (SD 0.55). The mean clearance of gadodiamide during hemodialysis was 63.5 ml/min (SD 21.9). There were no side effects related to the injection of gadodiamide. In all cases, diagnosable MRI and MRA images were obtained after gadodiamide injection in the hemodialysis patients.CONCLUSION: In hemodialysis patients, gadodiamide achieves diagnosable images. It is dialyzable and can be used safely without measures to increase excretion.